These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

474 related articles for article (PubMed ID: 29476703)

  • 1. The use of anti-Müllerian hormone for controlled ovarian stimulation in assisted reproductive technology, fertility assessment and -counseling.
    Pilsgaard F; Grynnerup AG; Løssl K; Bungum L; Pinborg A
    Acta Obstet Gynecol Scand; 2018 Sep; 97(9):1105-1113. PubMed ID: 29476703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-Müllerian Hormone and Its Predictive Utility in Assisted Reproductive Technologies Outcomes.
    Granger E; Tal R
    Clin Obstet Gynecol; 2019 Jun; 62(2):238-256. PubMed ID: 30994481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-Müllerian hormone versus antral follicle count for defining the starting dose of FSH.
    Lan VT; Linh NK; Tuong HM; Wong PC; Howles CM
    Reprod Biomed Online; 2013 Oct; 27(4):390-9. PubMed ID: 23953069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of anti-Müllerian hormone assessment in assisted reproductive technology outcome.
    Broer SL; Mol B; Dólleman M; Fauser BC; Broekmans FJ
    Curr Opin Obstet Gynecol; 2010 Jun; 22(3):193-201. PubMed ID: 20407372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Infertile women below the age of 40 have similar anti-Müllerian hormone levels and antral follicle count compared with women of the same age with no history of infertility.
    Hvidman HW; Bentzen JG; Thuesen LL; Lauritsen MP; Forman JL; Loft A; Pinborg A; Nyboe Andersen A
    Hum Reprod; 2016 May; 31(5):1034-45. PubMed ID: 26965431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The addition of anti-Müllerian hormone in an algorithm for individualized hormone dosage did not improve the prediction of ovarian response-a randomized, controlled trial.
    Magnusson Å; Nilsson L; Oleröd G; Thurin-Kjellberg A; Bergh C
    Hum Reprod; 2017 Apr; 32(4):811-819. PubMed ID: 28175316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The physiology and clinical utility of anti-Mullerian hormone in women.
    Dewailly D; Andersen CY; Balen A; Broekmans F; Dilaver N; Fanchin R; Griesinger G; Kelsey TW; La Marca A; Lambalk C; Mason H; Nelson SM; Visser JA; Wallace WH; Anderson RA
    Hum Reprod Update; 2014; 20(3):370-85. PubMed ID: 24430863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fertility in women of late reproductive age: the role of serum anti-Müllerian hormone (AMH) levels in its assessment.
    Meczekalski B; Czyzyk A; Kunicki M; Podfigurna-Stopa A; Plociennik L; Jakiel G; Maciejewska-Jeske M; Lukaszuk K
    J Endocrinol Invest; 2016 Nov; 39(11):1259-1265. PubMed ID: 27300031
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessing ovarian response: antral follicle count versus anti-Müllerian hormone.
    Fleming R; Seifer DB; Frattarelli JL; Ruman J
    Reprod Biomed Online; 2015 Oct; 31(4):486-96. PubMed ID: 26283017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation of age and antimullerian hormone in assisted reproductive technology program outcome.
    Himabindu Y; Gopinathan KK; Pandey AK; Sriharibabu M
    Indian J Physiol Pharmacol; 2013; 57(1):9-15. PubMed ID: 24020093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-Müllerian hormone (AMH) is a strong predictor of live birth in women undergoing assisted reproductive technology.
    Lukaszuk K; Liss J; Kunicki M; Jakiel G; Wasniewski T; Woclawek-Potocka I; Pastuszek E
    Reprod Biol; 2014 Sep; 14(3):176-81. PubMed ID: 25152514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AMH type II receptor and AMH gene polymorphisms are not associated with ovarian reserve, response, or outcomes in ovarian stimulation.
    Cerra C; Newman WG; Tohlob D; Byers H; Horne G; Roberts SA; Mohiyiddeen L
    J Assist Reprod Genet; 2016 Aug; 33(8):1085-91. PubMed ID: 27142041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-Müllerian hormone: ovarian reserve testing and its potential clinical implications.
    Broer SL; Broekmans FJ; Laven JS; Fauser BC
    Hum Reprod Update; 2014; 20(5):688-701. PubMed ID: 24821925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART).
    La Marca A; Sighinolfi G; Radi D; Argento C; Baraldi E; Artenisio AC; Stabile G; Volpe A
    Hum Reprod Update; 2010; 16(2):113-30. PubMed ID: 19793843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A prospective, comparative analysis of anti-Müllerian hormone, inhibin-B, and three-dimensional ultrasound determinants of ovarian reserve in the prediction of poor response to controlled ovarian stimulation.
    Jayaprakasan K; Campbell B; Hopkisson J; Johnson I; Raine-Fenning N
    Fertil Steril; 2010 Feb; 93(3):855-64. PubMed ID: 19046583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AMH as the primary marker for fertility.
    Dewailly D; Laven J
    Eur J Endocrinol; 2019 Dec; 181(6):D45-D51. PubMed ID: 31398713
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ovarian reserve assessment in users of oral contraception seeking fertility advice on their reproductive lifespan.
    Birch Petersen K; Hvidman HW; Forman JL; Pinborg A; Larsen EC; Macklon KT; Sylvest R; Andersen AN
    Hum Reprod; 2015 Oct; 30(10):2364-75. PubMed ID: 26311148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of the lower serum anti-Müllerian hormone threshold for ovarian stimulation prior to in-vitro fertilization using the Elecsys® AMH assay: a prospective observational study.
    Grynnerup AG; Løssl K; Pilsgaard F; Lunding SA; Storgaard M; Bogstad JW; Prætorius L; Zedeler A; Bungum L; Nyboe Andersen A; Pinborg A
    Reprod Biol Endocrinol; 2019 Jan; 17(1):11. PubMed ID: 30634990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-Müllerian hormone dynamics during GNRH-antagonist short protocol for IVF/ICSI in women with varying ovarian reserve levels.
    Melado Vidales L; Fernández-Nistal A; Martínez Fernández V; Verdú Merino V; Bruna Catalán I; Bajo Arenas JM
    Minerva Ginecol; 2017 Apr; 69(2):128-134. PubMed ID: 27310675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical pregnancy in a woman with idiopathic hypogonadotropic hypogonadism and low AMH: utility of ovarian reserve markers in IHH.
    Chan C; Liu K
    J Assist Reprod Genet; 2014 Oct; 31(10):1317-21. PubMed ID: 25113621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.